Physician profile
Manny Lai
NPI 1669836037
$4,242.24
in general payments reported to CMS, 2019-2025
26 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.60 · 2021: $30.24 · 2022: $1,405 · 2023: $858 · 2024: $1,395 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $868.97 | 2021-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $453.17 | 2022-2025 | Ztlido |
| Valinor Pharma, LLC | $407.08 | 2023-2025 | Movantik |
| Medtronic, INC. | $391.55 | 2022-2023 | Vanta Adaptivestim, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $364.07 | 2022-2025 | Belbuca, Xtampza |
| Nevro Corp. | $323.41 | 2024 | Senza |
| Boston Scientific Corporation | $176.58 | 2022-2025 | Wavewriter Alpha Prime 16, Intracept |
| Mml US, INC. | $144.35 | 2022 | |
| Pfizer INC. | $137.67 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $133.05 | 2022 | |
| Vertos Medical, INC. | $116.50 | 2022-2024 | Mild Device Kit |
| Spr Therapeutics, INC | $109.76 | 2022 | |
| Ibsa Pharma INC. | $104.52 | 2022-2024 | Tirosint, Licart, Licart |
| Relievant Medsystems, INC. | $102.15 | 2022 | |
| Electronic Waveform Lab, INC. | $87.98 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $79.60 | 2025 | Wainua |
| Globus Medical, INC. | $42.09 | 2025 | Senza |
| Medtronic USA, INC. | $39.60 | 2020 | |
| Redhill Biopharma INC. | $37.83 | 2022 | |
| Appliedvr INC | $33.98 | 2025 | Relievrx |
| Amneal Pharmaceuticals LLC | $19.26 | 2023 | Lyvispah |
| International Rehabilitative Sciences, INC | $15.31 | 2024 | Rs 4i Plus Sequential Stimulator |
| Tonix Medicines, INC. | $15.17 | 2025 | Tonmya |
| Teva Pharmaceuticals USA, INC. | $13.72 | 2023 | Austedo Xr |
| Abbvie INC. | $13.52 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manny Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.